{"nctId":"NCT01041859","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","startDateStruct":{"date":"2009-12"},"conditions":["Diabetic Peripheral Neuropathy"],"count":460,"armGroups":[{"label":"Tapentadol Extended Release (ER)","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol extended release (ER)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tapentadol extended release (ER)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with Type 1 or 2 diabetes mellitus must have a documented clinical diagnosis of painful diabetic peripheral neuropathy with symptoms and signs for at least 6 months, and pain present at the time of screening\n* Diagnosis must include pain plus reduction or absence of pin sensibility and/or vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower and/or upper extremities at screening\n* The investigator considers the patient's blood glucose to be controlled by diet, or hypoglycemics, or insulin for at least 3 months prior to enrolling in the study\n* Patients have been taking analgesic medications for the condition for at least 3 months prior to screening (patients taking opioid analgesics must be dissatisfied with current treatment, and patients taking non-opioid analgesics must be dissatisfied with current analgesia)\n* Patients currently requiring opioid treatment must be taking daily doses of an opioid-based analgesic equivalent to \\<=160mg of oral morphine\n\nExclusion Criteria:\n\n* Significant history of pulmonary, gastrointestinal, endocrine, metabolic (except diabetes mellitus), neurological, psychiatric disorders (resulting in disorientation, memory impairment or inability to report accurately as in schizophrenia)\n* History of moderate to severe hepatic impairment\n* Severely impaired renal function\n* Clinically significant laboratory abnormalities\n* Clinically significant cardiac disease\n* History of seizure disorder or epilepsy\n* History of any other clinically significant disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise patient safety during study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12","description":"For this twice daily pain assessment, the patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"2.04"},{"groupId":"OG001","value":"1.3","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Responder Analysis: Proportion of Patients With At Least 50% Improvement From Baseline of Open-Label on the Numerical Rating Scale (NRS) at the Week 12 Endpoint","description":"The NRS was a twice-daily pain assessment in which patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point scale with a score of 0 indicating \"no pain\" and a score of 10 indicating \"pain as bad as you can imagine\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":"2.04"},{"groupId":"OG001","value":"28.9","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Distribution of Patient Global Impression of Change at Week 12 Endpoint","description":"Patient Global Impression of Change (PGIC) is a patient-rated assessment of overall neuropathic pain since the start of treatment using a categorical scale 1-7, where 1 is 'very much improved' and 7 is 'very much worse'","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":"2.04"},{"groupId":"OG001","value":"14.4","spread":"2.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"30.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"20.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Open-Label in the Pain Intensity Subscale of the Brief Pain Inventory (BPI) at the Week 12 Double-Blind Endpoint","description":"The BPI is a 12-item questionnaire to evaluate the intensity of pain and the degree to which pain interferes with function. It includes 4 items assessing current pain intensity and pain at its worst, least, and on average over the past day using an 11-point scale from 0 = no pain to 10 = pain as bad as you can imagine. The pain intensity subscale score is defined as the mean of the scores from these 4 items.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"2.16"},{"groupId":"OG001","value":"-2.3","spread":"2.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint","description":"EQ-5D has 5 items (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) rated on a categorical scale of 1-3 with 1=no problems, 2=some problems, 3=extreme problems. The health state index is a weighted combination of the 5 items. It has a range of 0 to 1, with 0=deceased and 1=full health.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.203"},{"groupId":"OG001","value":"-0.10","spread":"0.257"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":459},"commonTop":["Nausea","Dizziness","Vomiting","Constipation","Somnolence"]}}}